News

FDA Clears IND for SEED Therapeutics’ RBM39 Degrader ST-01156
First Patient Dosing Expected in Q1 2026 • Clinical Trial to Prioritize Biomarker-Selected RBM39-Dependent Cancers KING OF ...
Amphastar Announces FDA Approval for Iron Sucrose Injection, USP
According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to ...
Amphastar Pharmaceuticals, Inc.: Amphastar Announces FDA Approval for Iron Sucrose Injection, USP
According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to Venofer® for the treatment of iron deficiency anemia in patients with chro ...
Alzinova AB: Alzinova submits applications for clinical trial initiation (IND) and Fast Track status to the FDA
Alzinova AB (publ) (Nasdaq First North: ALZ) today announced that the company has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for the planned P ...
GSK's antibiotic gets FDA priority review for oral treatment of gonorrhoea
British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority ...
GSK's antibiotic drug gepotidacin gets priority review by FDA
British drugmaker GSK said on Monday its supplemental new drug application for antibiotic drug gepotidacin has been accepted for priority review by the U.S. Food and Drug Administration for the oral ...
MyChesCo on MSN20h
FDA Launches PreCheck Program to Boost Domestic Drug Manufacturing
The U.S. Food and Drug Administration has unveiled FDA PreCheck, a new initiative designed to strengthen the domestic ...